Abstract 969P
Background
Alpha-fetoprotein (AFP) is widely used for HCC screening in at-risk populations, but its performance is suboptimal. Routine blood test panels provide insights on multiple cancer-related conditions and have shown to improve detection in other cancers. Hence, we explore the foundation for a new high-dimensional data approach taking multiple routine laboratory parameters and their intricate interactions into consideration with AI. In this study, a routine blood test signature for HCC derived from big clinical data is described
Methods
This is a population-based retrospective study. Patient records from 2000 to 2018 were retrieved from the Hong Kong Hospital Authority Data Collaboration Laboratory. CLD patients with and without HCC were identified based on ICD codes, antiviral drug history, virology test and radiology reports. Patients with decompensated CLD were excluded. Routine blood tests retrieved included CBC, LFT, RFT and clotting profile. Blood records within one month before the diagnosis of HCC and CLD patients were retrieved. Statistical analysis included descriptive statistics and Mann-Whitney U (MWU) test.
Results
The cohort yielded 223,862 patients including 31,149 patients with HCC (13.9%) and 192,713 without. Statistical test results showed a distinctive spectral signature for HCC patients compared to those without HCC. It is characterized by the concurrent presence of more significant liver function derangement (raised ALT, ALP, bilirubin, AST and decreased albumin), tendency for systemic inflammation (lower lymphocyte and RDW), tendency for bleeding (prolonged PT and APTT, low platelet) and suggestions of cachexia (lower albumin, creatinine and urea), all were statistically significant (P<0.05, MWU test)
Conclusions
This is the first study to describe a routine blood signature for HCC detection established by big clinical data. The spectral characteristics of HCC separated well from CLD controls. The novel spectrum provides solid clinical ground for the use of advanced machine learning to generate an interactive classification model to detect HCC. In a companion abstract, we describe the development of the proposed signature, which is shown to be superior to AFP in HCC screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong University of Science and Technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18